<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04463940</url>
  </required_header>
  <id_info>
    <org_study_id>0024-19-BRZ</org_study_id>
    <nct_id>NCT04463940</nct_id>
  </id_info>
  <brief_title>Xanthine Oxidase and Uric Acid Origin in Preeclamptic Women</brief_title>
  <official_title>The Origin of Xanthine Oxidase and Its Metabolite, Uric Acid, in Preeclamptic Pregnant Women - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barzilai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barzilai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Findings regarding the presence of xanthine oxidase and uric acid in different blood
      locations is important in preeclamptic women. We aim to detecting Xanthine oxidase and uric
      acid levels in both umbilical cord artery and vein as well as maternal blood (3 &quot;locations&quot;)
      in pregnant women with and without diagnosis of preeclampsia. The study population will be
      divided into groups matching the three &quot;locations&quot; in order to describe and compare outcome
      levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Significance - findings regarding the presence of xanthine oxidase and uric acid in different
      blood locations may provide a scientific basis for understanding the source of them in
      preeclamptic women. Aim - detecting Xanthine oxidase and uric acid levels in both umbilical
      cord artery and vein as well as maternal blood (3 &quot;locations&quot;). Methods - samples will be
      collected from pregnant women with and without diagnosis of preeclampsia with blood uric acid
      &gt; 6 mg/dL. Than the study population will be divided into groups matching the three
      &quot;locations&quot;. The investigators will describe and compare outcome levels (including Xanthine
      oxidase, uric acid).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Uric Acid</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>mg/dL</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pre-Eclampsia</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Umbilical cord arterial blood</arm_group_label>
    <description>participant's umbilical cord arterial blood will be obtained</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Umbilical cord venus blood</arm_group_label>
    <description>participant's umbilical cord Venus blood will be obtained</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maternal blood</arm_group_label>
    <description>participant's blood will be obtained</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Maternal blood</arm_group_label>
    <arm_group_label>Umbilical cord arterial blood</arm_group_label>
    <arm_group_label>Umbilical cord venus blood</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women with and without diagnosis of Pre-Eclampsia and serum Uric Acid greater than
        6 mg/dL
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  preeclampsia and none-preeclampsia diagnosed pregnant women.

        Exclusion Criteria:

          -  Known or reported kidney disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Simon Shenhav, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barzilai University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yaniv Ovadia, Dr</last_name>
    <phone>+ 972 (0) 8 6745220</phone>
    <email>yanivo@bmc.gov.il</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barzilai Medical Center</investigator_affiliation>
    <investigator_full_name>Simon Shanhav</investigator_full_name>
    <investigator_title>Dr Simon Shenhav, head of High Risk Pregnancy Unit</investigator_title>
  </responsible_party>
  <keyword>Xanthine oxidase</keyword>
  <keyword>Uric acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

